Pages that link to "Q77952254"
Jump to navigation
Jump to search
The following pages link to Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor (Q77952254):
Displaying 17 items.
- Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions (Q24532135) (← links)
- Principles of tumor immunosurveillance and implications for immunotherapy (Q35043113) (← links)
- Targeted immunotherapy of cancer: development of antibody-induced cellular immunity. (Q35084986) (← links)
- Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. (Q35437978) (← links)
- Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases. (Q35635268) (← links)
- Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. (Q35829136) (← links)
- Immunological ignorance of solid tumors (Q36167785) (← links)
- Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells (Q36376481) (← links)
- The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy (Q36402637) (← links)
- Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 CpG (Q36625824) (← links)
- Early detection of tumour immune-rejection using magnetic resonance imaging (Q36646743) (← links)
- Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo (Q40332957) (← links)
- Fc gamma receptors and cross-presentation in dendritic cells (Q42947596) (← links)
- Optimism after much pessimism: what next? (Q51085661) (← links)
- Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma (Q74336550) (← links)
- Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity (Q79338067) (← links)
- PD-1 blockade enhances elotuzumab efficacy in mouse tumor models (Q89776901) (← links)